A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)

Description:

This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.

Sponsor:

Advanced Accelerator Applications

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

Government Study Link:

NCT04711135 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

🇺🇸 United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania 19104, United States

Cincinnati Children's Hospital Medical Centre

Cincinnati, Ohio 45229, United States

University of Kentucky

Lexington, Kentucky 40536, United States

🇦🇫 Afghanistan

University College Hospital of London

🇫🇷 France

Centre Léon Bérard

Lyon, Rhône, France

🇵🇱 Poland

Maria Sklodowska-Curie National Research Institute of Oncology

Gliwice, Silesian Voivodeship, Poland

🇪🇸 Spain

Ciutat Sanitaria i Universitaria de la Vall d'Hebron

Barcelona, Spain

Contact XCancer: 402-991-8468